

Docket No. 10806-156

PATENT

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Box Missing Parts; Commissioner of Patents, Washington, DC 20231 on March 12, 2002.

Laureen E. Maens

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Anneli Attersand : Paper No.:
Serial No.: 10/029,359 : Group Art Unit: 1645
Filing Date: December 21, 2001 : Examiner:
For: **Protein Cluster II**

TRANSMITTAL OF CERTIFIED PRIORITY DOCUMENT

Box Missing Parts
Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Submitted herewith is a certified copy of Swedish priority application No. 0004828-0 filed December 22, 2000. The priority document is in the English language. It is believed that this satisfies the requirements of 35 U.S.C. §119.

Respectfully submitted,

By Holly D. Kozlowski
Holly D. Kozlowski, Reg. No. 30,468
Attorney for Applicant
DINSMORE & SHOHL LLP
1900 Chemed Center
255 East Fifth Street
Cincinnati, Ohio 45202
(513) 977-8568

PRV

PATENT- OCH REGISTRERINGSVERKET

Patentavdelningen



COPY OF PAPERS
ORIGINALLY FILED

Intyg Certificate

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.



(71) Sökande Pharmacia AB, Stockholm SE
Applicant (s)

(21) Patentansökningsnummer 0004828-0
Patent application number

(86) Ingivningsdatum 2000-12-22
Date of filing

Stockholm, 2001-12-17

För Patent- och registreringsverket
For the Patent- and Registration Office


Christina Vängborg

Avgift
Fee 170:-

**PATENT- OCH
REGISTRERINGSVERKET
SWEDEN**

Postadress/Adress
Box 5055
S-102 42 STOCKHOLM

Telefon/Phone
+46 8 782 25 00
Vx 08-782 25 00

Telex
17978
PATOREG S

Telefax
+46 8 666 02 86
08-666 02 86

PROTEIN CLUSTER II

TECHNICAL FIELD

The present invention relates to the identification of a human gene family expressed in metabolically relevant tissues. The genes encode a group polypeptides referred to as "Protein Cluster II" which are predicted to be useful in the diagnosis of metabolic diseases, such as obesity and diabetes, as well as in the identification of agents useful in the treatment of the said diseases.

BACKGROUND ART

Metabolic diseases are defined as any of the diseases or disorders that disrupt normal metabolism. They may arise from nutritional deficiencies; in connection with diseases of the endocrine system, the liver, or the kidneys; or as a result of genetic defects. Metabolic diseases are conditions caused by an abnormality in one or more of the chemical reactions essential to producing energy, to regenerating cellular constituents, or to eliminating unneeded products arising from these processes. Depending on which metabolic pathway is involved, a single defective chemical reaction may produce consequences that are narrow, involving a single body function, or broad, affecting many organs and systems.

One of the major hormones that influence metabolism is insulin, which is synthesized in the beta cells of the islets of Langerhans of the pancreas. Insulin primarily regulates the direction of metabolism, shifting many processes toward the storage of substrates and away from their degradation. Insulin acts to increase the transport of glucose and amino acids as well as key minerals such as potassium, magnesium, and phosphate from the blood into cells. It also regulates a variety of enzymatic reactions within the cells, all of which have a common overall direction, namely the synthesis of large molecules from small units. A deficiency in the action of insulin (diabetes mellitus) causes severe impairment in (i) the storage of glucose in the form of glycogen and the oxidation of

glucose for energy; (ii) the synthesis and storage of fat from fatty acids and their precursors and the completion of fatty-acid oxidation; and (iii) the synthesis of proteins from amino acids.

There are two varieties of diabetes. Type I is insulin-dependent diabetes mellitus (IDDM), for which insulin injection is required; it was formerly referred to as juvenile onset diabetes. In this type, insulin is not secreted by the pancreas and hence must be taken by injection. Type II, non-insulin-dependent diabetes mellitus (NIDDM) may be controlled by dietary restriction. It derives from insufficient pancreatic insulin secretion and tissue resistance to secreted insulin, which is complicated by subtle changes in the secretion of insulin by the beta cells. Despite their former classifications as juvenile or adult, either type can occur at any age; NIDDM, however, is the most common type, accounting for 90 percent of all diabetes. While the exact causes of diabetes remain obscure, it is evident that NIDDM is linked to heredity and obesity. There is clearly a genetic predisposition to NIDDM diabetes in those who become overweight or obese.

Obesity is usually defined in terms of the body mass index (BMI), i.e. weight (in kilograms) divided by the square of the height (in meters). Weight is regulated with great precision. Regulation of body weight is believed to occur not only in persons of normal weight but also among many obese persons, in whom obesity is attributed to an elevation in the set point around which weight is regulated. The determinants of obesity can be divided into genetic, environmental, and regulatory.

Recent discoveries have helped explain how genes may determine obesity and how they may influence the regulation of body weight. For example, mutations in the *ob* gene have led to massive obesity in mice. Cloning the *ob* gene led to the identification of leptin, a protein coded by this gene; leptin is produced in adipose tissue cells and acts to control body fat. The existence of leptin supports the idea that body weight is regulated, because leptin serves as a signal between adipose tissue and the areas of the brain that control energy metabolism, which influences body weight.

Metabolic diseases like diabetes and obesity are clinically and genetically heterogeneous disorders. Recent advances in molecular genetics have led to the recognition of genes involved in IDDM and in some subtypes of NIDDM, including maturity-onset diabetes of the young (MODY) (Velho & Froguel (1997) Diabetes Metab. 23 Suppl 2:34-37). However, several IDDM susceptibility genes have not yet been identified, and very little is known about genes contributing to common forms of NIDDM. Studies of candidate genes and of genes mapped in animal models of IDDM or NIDDM, as well as whole genome scanning of diabetic families from different populations, should allow the identification of most diabetes susceptibility genes and of the molecular targets for new potential drugs. The identification of genes involved in metabolic disorders will thus contribute to the development of novel predictive and therapeutic approaches.

DESCRIPTION OF THE INVENTION

According to the present invention, a family of genes and encoded homologous proteins (hereinafter referred to as "Protein Cluster II") has been identified. Consequently, the present invention provides an isolated nucleic acid molecule selected from:

- (a) nucleic acid molecules comprising a nucleotide sequence as shown in SEQ ID NO: 1, or 3;
- (b) nucleic acid molecules comprising a nucleotide sequence capable of hybridizing, under stringent hybridization conditions, to a nucleotide sequence complementary to the polypeptide coding region of a nucleic acid molecule as defined in (a); and
- (c) nucleic acid molecules comprising a nucleic acid sequence which is degenerate as a result of the genetic code to a nucleotide sequence as defined in (a) or (b).

The nucleic acid molecules according to the present invention includes cDNA, chemically synthesized DNA, DNA isolated by PCR, genomic DNA, and combinations thereof. RNA transcribed from DNA is also encompassed by the present invention.

The term "stringent hybridization conditions" is known in the art from standard protocols (e.g. Ausubel et al., *supra*) and could be understood as e.g. hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at +65°C, and washing in 0.1xSSC / 0.1% SDS at +68°C.

In a preferred form of the invention, the said nucleic acid molecule has a nucleotide sequence identical with SEQ ID NOS: 1 or 3 of the Sequence Listing. However, the nucleic acid molecule according to the invention is not to be limited strictly to the sequence shown as SEQ ID NOS: 1 or 3. Rather the invention encompasses nucleic acid molecules carrying modifications like substitutions, small deletions, insertions or inversions, which nevertheless encode proteins having substantially the features of the Protein Cluster II polypeptide according to the invention. Included in the invention are consequently nucleic acid molecules, the nucleotide sequence of which is at least 90% homologous, preferably at least 95% homologous, with the nucleotide sequence shown as SEQ ID NOS: 1 or 3 in the Sequence Listing.

Included in the invention is also a nucleic acid molecule which nucleotide sequence is degenerate, because of the genetic code, to the nucleotide sequence shown as SEQ ID NO: 1 or 3. A sequential grouping of three nucleotides, a "codon", codes for one amino acid. Since there are 64 possible codons, but only 20 natural amino acids, most amino acids are coded for by more than one codon. This natural "degeneracy", or "redundancy", of the genetic code is well known in the art. It will thus be appreciated that the nucleotide sequence shown in the Sequence Listing is only an example within a large but definite group of sequences which will encode the Protein Cluster II polypeptide.

The nucleic acid molecules according to the invention have numerous applications in techniques known to those skilled in the art of molecular biology. These techniques include their use as hybridization probes, for chromosome and gene mapping, in PCR technologies, in the production of sense or antisense nucleic acids, in screening for new therapeutic molecules, etc.

More specifically, the sequence information provided by the invention makes possible large-scale expression of the encoded polypeptides by techniques well known in the art. Nucleic acid molecules of the invention also permit identification and isolation of nucleic acid molecules encoding related polypeptides, such as human allelic variants and species homologues, by well-known techniques including Southern and/or Northern hybridization, and PCR. Knowledge of the sequence of a human DNA also makes possible, through use of Southern hybridization or PCR, the identification of genomic DNA sequences encoding the proteins in Cluster II, expression control regulatory sequences such as promoters, operators, enhancers, repressors, and the like. Nucleic acid molecules of the invention are also useful in hybridization assays to detect the capacity of cells to express the proteins in Cluster II. Nucleic acid molecules of the invention may also provide a basis for diagnostic methods useful for identifying a genetic alteration(s) in a locus that underlies a disease state or states, which information is useful both for diagnosis and for selection of therapeutic strategies.

In a further aspect, the invention provides an isolated polypeptide encoded by the nucleic acid molecule as defined above. In a preferred form, the said polypeptide has an amino acid sequence according to SEQ ID NO: 2 or 4 of the Sequence Listing. However, the polypeptide according to the invention is not to be limited strictly to a polypeptide with an amino acid sequence identical with SEQ ID NO: 2 or 4 in the Sequence Listing. Rather the invention encompasses polypeptides carrying modifications like substitutions, small deletions, insertions or inversions, which polypeptides nevertheless have substantially the features of the Protein Cluster II polypeptide. Included in the invention are consequently polypeptides, the amino acid sequence of which is at least 90% homologous, preferably at least 95% homologous, with the amino acid sequence shown as SEQ ID NO: 2 or 4 in the Sequence Listing.

In a further aspect, the invention provides a vector harboring the nucleic acid molecule as defined above. The said vector can e.g. be a replicable expression vector, which carries and is capable of mediating the expression of a DNA molecule according to the invention. In the present context the term "replicable" means that the vector is able to replicate in a given type of host cell into which it has been introduced. Examples of

vectors are viruses such as bacteriophages, cosmids, plasmids and other recombination vectors. Nucleic acid molecules are inserted into vector genomes by methods well known in the art.

Included in the invention is also a cultured host cell harboring a vector according to the invention. Such a host cell can be a prokaryotic cell, a unicellular eukaryotic cell or a cell derived from a multicellular organism. The host cell can thus e.g. be a bacterial cell such as an *E. coli* cell; a cell from a yeast such as *Saccharomyces cerevisiae* or *Pichia pastoris*, or a mammalian cell. The methods employed to effect introduction of the vector into the host cell are standard methods well known to a person familiar with recombinant DNA methods.

In yet another aspect, the invention provides a process for production of a polypeptide, comprising culturing a host cell, according to the invention, under conditions whereby said polypeptide is produced, and recovering said polypeptide. The medium used to grow the cells may be any conventional medium suitable for the purpose. A suitable vector may be any of the vectors described above, and an appropriate host cell may be any of the cell types listed above. The methods employed to construct the vector and effect introduction thereof into the host cell may be any methods known for such purposes within the field of recombinant DNA. The recombinant polypeptide expressed by the cells may be secreted, i.e. exported through the cell membrane, dependent on the type of cell and the composition of the vector.

In a further aspect, the invention provides a method for identifying an agent capable of modulating a nucleic acid molecule according to the invention, comprising

- (i) providing a cell comprising the said nucleic acid molecule;
- (ii) contacting said cell with a candidate agent; and
- (iii) monitoring said cell for an effect that is not present in the absence of said candidate agent.

For screening purposes, appropriate host cells can be transformed with a vector having a reporter gene under the control of the nucleic acid molecule according to this invention.

The expression of the reporter gene can be measured in the presence or absence of an agent with known activity (i.e. a standard agent) or putative activity (i.e. a "test agent" or "candidate agent"). A change in the level of expression of the reporter gene in the presence of the test agent is compared with that effected by the standard agent. In this way, active agents are identified and their relative potency in this assay determined.

A transfection assay can be a particularly useful screening assay for identifying an effective agent. In a transfection assay, a nucleic acid containing a gene such as a reporter gene that is operably linked to a nucleic acid molecule according to the invention, is transfected into the desired cell type. A test level of reporter gene expression is assayed in the presence of a candidate agent and compared to a control level of expression. An effective agent is identified as an agent that results in a test level of expression that is different than a control level of reporter gene expression, which is the level of expression determined in the absence of the agent. Methods for transfecting cells and a variety of convenient reporter genes are well known in the art (see, for example, Goeddel (ed.), *Methods Enzymol.*, Vol. 185, San Diego: Academic Press, Inc. (1990); see also Sambrook, *supra*).

Throughout this description the terms "standard protocols" and "standard procedures", when used in the context of molecular biology techniques, are to be understood as protocols and procedures found in an ordinary laboratory manual such as: *Current Protocols in Molecular Biology*, editors F. Ausubel et al., John Wiley and Sons, Inc. 1994, or Sambrook, J., Fritsch, E.F. and Maniatis, T., *Molecular Cloning: A laboratory manual*, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1989.

Additional features of the invention will be apparent from the following Examples. Examples 1 to 3 are actual, while Examples 4 to 9 are prophetic.

1
2
3
4
5
6
7
8
9

EXAMPLES

EXAMPLE 1: Identification of protein clusters

A family of homologous proteins (hereinafter referred to as "Protein Cluster II") was identified by an "all-versus-all" BLAST procedure using all *Caenorhabditis elegans* proteins in the Wormpep20 database release (http://www.sanger.ac.uk/Projects/C_elegans/wormpep/index.shtml). The Wormpep database contains the predicted proteins from the *C. elegans* genome sequencing project, carried out jointly by the Sanger Centre in Cambridge, UK and the Genome Sequencing Center in St. Louis, USA. A number of 18,940 proteins were retrieved from Wormpep20. The proteins were used in a Smith-Waterman clustering procedure to group together proteins of similarity (Smith T.F. & Waterman M.S. (1981) *Identification of common molecular subsequences*. J. Mol. Biol. 147(1): 195-197; Pearson WR. (1991) *Searching protein sequence libraries: comparison of the sensitivity and selectivity of the Smith-Waterman and FASTA algorithms*. Genomics 11: 635-650; Olsen et al. (1999) *Optimizing Smith-Waterman alignments*. Pac Symp Biocomput. 302-313). Completely annotated proteins were filtered out, whereby 10,130 proteins of unknown function could be grouped into 1,800 clusters.

The obtained sequence clusters were compared to the *Drosophila melanogaster* proteins contained in the database Flybase (Berkeley Drosophila Genome Project; <http://www.fruitfly.org>), and annotated clusters were removed. Non-annotated protein clusters, conserved in both *C. elegans* and *D. melanogaster*, were saved to a worm/fly data set, which was used in a BLAST procedure (<http://www.ncbi.nlm.nih.gov/Education/BLASTinfo/information3.html>) against the Celera Human Genome Database (<http://www.celera.com>). Overlapping fragments were assembled to, as close as possible, full-length proteins using the PHRAP software, developed at the University of Washington (http://www.genome.washington.edu/UWGC/analysis_tools/phrap.htm). A group of homologous proteins ("Protein Cluster II") with unknown function was chosen for further studies.

EST databases provided by the EMBL (<http://www.embl.org/Services/index.html>) were used to check whether the human proteins in Cluster II were expressed, in order to identify putative pseudogenes. One putative pseudogene was identified and excluded.

EXAMPLE 2: Analyses of Protein Cluster II

(a) Alignment

The human part of Protein Cluster II comprises polypeptides encoded by the nucleic acid sequences shown as SEQ ID NOS: 1, 3 and 5. The sequence shown as SEQ ID NO: 5 was identified as the gene annotated as *Homo sapiens* core1 UDP-galactose:N-acetylgalactosamine-alpha-R beta 1,3-galactosyltransferase (C1GALT1; GenBank Accession No. AF155582; see also International Patent Application No. WO 99/65712.)

An alignment of the human polypeptides included in Protein Cluster II (SEQ ID NOS: 2, 4, and 6), using the ClustalW multiple alignment software (Thompson et al. (1994) Nucleic Acid Research 22: 4673-4680) is shown in Table I. The alignment showed a high degree of conservation in a distinct part of the protein cluster II, indicating the presence of a novel domain (see positions marked with stars in Table I).

The sequence shown as SEQ ID NO: 6 is identical to positions 53-363 of the polypeptide encoded by the C1GALT1 gene mentioned above.

(b) HMM-Pfam

A HMM-Pfam search was performed on the human family members. Pfam is a large collection of protein families and domains. Pfam contains multiple protein alignments and profile-HMMs (Profile Hidden Markov Models) of these families. Profile-HMMs can be used to do sensitive database searching using statistical descriptions of a sequence family's consensus. Pfam is available on the WWW at <http://pfam.wustl.edu>; <http://www.sanger.ac.uk/Software/Pfam>; and <http://www.cgr.ki.se/Pfam>. The latest

version (4.3) of Pfam contains 1815 families. These Pfam families match 63% of proteins in SWISS-PROT 37 and TrEMBL 9. For references to Pfam, see Bateman et al. (2000) *The Pfam protein families database*. Nucleic Acids Res. 28:263-266; Sonnhammer et al. (1998) *Pfam: Multiple Sequence Alignments and HMM-Profiles of Protein Domains*. Nucleic Acids Research, 26:322-325; Sonnhammer et al. (1997) *Pfam: a Comprehensive Database of Protein Domain Families Based on Seed Alignments*. Proteins 28:405-420.

The HMM-Pfam search indicated that no previously known domains could be identified in Protein Cluster II, with exception for a weak homology to Galactosyltransferase (Pfam Accession No. PF01762; see also Kolbinger et al. (1998) J. Biol. Chem. 273: 433-440).

A Pfam-B search revealed identity to the Pfam-B 7357 domain (Pfam Accession No. PB007357). Pfam-B domains are generated automatically from an alignment taken from the database ProDom 2000.1 (<http://www.linux.toulouse.inra.fr/prodom>) subtracting sequence segments already covered by Pfam-A. The ProDom database has been designed as tool to help analyze domain arrangements of proteins and protein families (Corpet et al. (1999) Nucleic Acid Research 27: 263-267). Pfam-B domains are curated manually at the Sanger Centre, UK, to become Pfam-A domains.

(c) TM-HMM

The human proteins in Cluster II were analyzed using the TM-HMM tool available e.g. at <http://www.cbs.dtu.dk/services/TMHMM-1.0>. TM-HMM is a method to model and predict the location and orientation of alpha helices in membrane-spanning proteins (Sonnhammer et al. (1998) *A hidden Markov model for predicting transmembrane helices in protein sequences*. ISMB 6:175-182). No transmembrane regions were identified.



(d) Analysis of non-human orthologs

The *Caenorhabditis elegans* genome includes eight genes encoding proteins within Protein Cluster II, of which the closest ancestor in evolution, a sequence included the *C. elegans* cosmid C38H2.2 (GenBank Accession No. Z35461) and annotated as UDP-galactose:N-acetylgalactosamine- α -R beta 1,3-galactosyltransferase mRNA (GenBank Accession No. AF269063) is 55%, 54%, and 42% identical to the three identified human proteins shown as SEQ ID NOS: 2, 4 and 6, respectively. (See also: *Genome sequence of the nematode C. elegans: a platform for investigating biology*; The *C. elegans* Sequencing Consortium. Science (1998) 282:2012-2018. Published errata appear in Science (1999) 283:35; 283:2103; and 285:1493.)

The *Drosophila melanogaster* genome comprises 10 genes belonging to Protein Cluster II, of which the closest relative "CG9520" (GenBank Accession No. AE003623; see also Adams et al. (2000) *The genome sequence of Drosophila melanogaster*; Science 287:2185-2195) is 42% identical to the human protein set.

No counterparts to Protein Cluster II in *Saccharomyces cerevisiae* were identified.

EXAMPLE 3: Expression analysis

The tissue distribution of the human genes was studied using the Incyte LifeSeq[®] database (<http://www.incyte.com>). The nucleic acid molecules shown as SEQ ID NO: 1, 3 and 5 were found to be expressed primarily in germ cells and in the nervous system. Therefore, the said nucleic acid molecules shown as SEQ ID NO: 1, 3 and 5 and the polypeptides shown as SEQ ID NO: 2, 4 and 6 are proposed to be useful for differential identification of the tissue(s) or cell types(s) present in a biological sample and for diagnosis of diseases and disorders, including disorders of the central nervous system.

EXAMPLE 4: Multiple Tissue Northern blotting

Multiple Tissue Northern blotting (MTN) is performed to make a more thorough analysis of the expression profiles of the proteins in Cluster II. Multiple Tissue Northern (MTN™) Blots (<http://www.clontech.com/mtn>) are pre-made Northern blots featuring Premium Poly A+ RNA from a variety of different human, mouse, or rat tissues. MTN Blots can be used to analyze size and relative abundance of transcripts in different tissues. MTN Blots can also be used to investigate gene families and alternate splice forms and to assess cross species homology.

EXAMPLE 5: Expressing profiling using microarrays

Microarrays consist of a highly ordered matrix of thousands of different DNA sequences that can be used to measure DNA and RNA variation in applications that include gene expression profiling, comparative genomics and genotyping (For recent reviews, see e.g.: Harrington et al. (2000) *Monitoring gene expression using DNA microarrays*. Curr. Opin. Microbiol. 3(3): 285-291; or Duggan et al. (1999) *Expression profiling using cDNA Microarrays*. Nature Genetics Supplement 21:10-14).

The expression pattern of the proteins in Cluster II can be analyzed using GeneChip® expression arrays (http://www.affymetrix.com/products/app_exp.html). Briefly, mRNAs are extracted from various tissues. They are reverse transcribed using a T7-tagged oligo-dT primer and double-stranded cDNAs are generated. These cDNAs are then amplified and labeled using In Vitro Transcription (IVT) with T7 RNA polymerase and biotinylated nucleotides. The populations of cRNAs obtained are purified and fragmented by heat to produce a distribution of RNA fragment sizes from approximately 35 to 200 bases. GeneChip® expression arrays are hybridized with the samples. The arrays are washed and stained. The cartridges are scanned using a confocal scanner and the images are analyzed with the GeneChip 3.1 software (Affymetrix).

EXAMPLE 6: Identification of polypeptides binding to Protein Cluster II

In order to assay for proteins interacting with Protein Cluster II, the two-hybrid screening method can be used. The two-hybrid method, first described by Fields & Song (1989) *Nature* 340:245-247, is a yeast-based genetic assay to detect protein-protein interactions *in vivo*. The method enables not only identification of interacting proteins, but also results in the immediate availability of the cloned genes for these proteins.

The two-hybrid method can be used to determine if two known proteins (i.e. proteins for which the corresponding genes have been previously cloned) interact. Another important application of the two-hybrid method is to identify previously unknown proteins that interact with a target protein by screening a two-hybrid library. For reviews, see e.g.: Chien et al. (1991) *The two-hybrid system: a method to identify and clone genes for proteins that interact with a protein of interest*. *Proc. Natl. Acad. Sci. U.S.A.* 88:9578-9582; Bartel PL, Fields (1995) *Analyzing protein-protein interactions using two-hybrid system*. *Methods Enzymol.* 254:241-263; or Wallach et al. (1998) *The yeast two-hybrid screening technique and its use in the study of protein-protein interactions in apoptosis*. *Curr. Opin. Immunol.* 10(2): 131-136. See also <http://www.clontech.com/matchmaker>.

The two-hybrid method uses the restoration of transcriptional activation to indicate the interaction between two proteins. Central to this technique is the fact that many eukaryotic transcriptional activators consist of two physically discrete modular domains: the DNA-binding domain (DNA-BD) that binds to a specific promoter sequence and the activation domain (AD) that directs the RNA polymerase II complex to transcribe the gene downstream of the DNA binding site. The DNA-BD vector is used to generate a fusion of the DNA-BD and a bait protein X, and the AD vector is used to generate a fusion of the AD and another protein Y. An entire library of hybrids with the AD can also be constructed to search for new or unknown proteins that interact with the bait protein. When interaction occurs between the bait protein X and a



candidate protein Y, the two functional domains, responsible for DNA binding and activation, are tethered, resulting in functional restoration of transcriptional activation. The two hybrids are cotransformed into a yeast host strain harboring reporter genes containing appropriate upstream binding sites; expression of the reporter genes then indicates interaction between a candidate protein and the target protein.

EXAMPLE 7: Full-length cloning of Cluster II genes

The polymerase chain reaction (PCR), which is a well known procedure for *in vitro* enzymatic amplification of a specific DNA segment, can be used for direct cloning of Protein Cluster II genes. Tissue cDNA can be amplified by PCR and cloned into an appropriate plasmid and sequenced. For reviews, see e.g. Hooft van Huijsduijnen (1998) *PCR-assisted cDNA cloning: a guided tour of the minefield*. Biotechniques 24:390-392; Lenstra (1995) *The applications of the polymerase chain reaction in the life sciences*. Cellular & Molecular Biology 41:603-614; or Rashtchian (1995) *Novel methods for cloning and engineering genes using the polymerase chain reaction*. Current Opinion in Biotechnology 6:30-36. Various methods for generating suitable ends to facilitate the direct cloning of PCR products are given e.g. in Ausubel et al. *supra* (section 15.7).

In an alternative approach to isolate a cDNA clone encoding a full length protein of Protein Cluster II, a DNA fragment corresponding to a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, 3, 5 or 7, or a portion thereof, can be used as a probe for hybridization screening of a phage cDNA library. The DNA fragment is amplified by the polymerase chain reaction (PCR) method. The primers are preferably 10 to 25 nucleotides in length and are determined by procedures well known to those skilled in the art. A lambda phage library containing cDNAs cloned into lambda phage-vectors is plated on agar plates with *E. coli* host cells, and grown. Phage plaques are transferred to nylon membranes, which are hybridized with a DNA probe prepared as described above. Positive colonies are isolated from the plates. Plasmids containing cDNA are rescued from the isolated phages by standard methods. Plasmid DNA is isolated from the clones. The size of the insert is determined by digesting the plasmid

with appropriate restriction enzymes. The sequence of the entire insert is determined by automated sequencing of the plasmids.

EXAMPLE 8: Recombinant expression of proteins in eukaryotic host cells

To produce proteins of Cluster II, a polypeptide-encoding nucleic acid molecule is expressed in a suitable host cell using a suitable expression vector and standard genetic engineering techniques. For example, the polypeptide-encoding sequence is subcloned into a commercial expression vector and transfected into mammalian, e.g. Chinese Hamster Ovary (CHO), cells using a standard transfection reagent. Cells stably expressing a protein are selected. Optionally, the protein may be purified from the cells using standard chromatographic techniques. To facilitate purification, antisera is raised against one or more synthetic peptide sequences that correspond to portions of the amino acid sequence, and the antisera is used to affinity purify the protein.

EXAMPLE 9: Determination of gene function

Methods are known in the art for elucidating the biological function or mode of action of individual genes. For instance, RNA interference (RNAi) offers a way of specifically and potentially inactivating a cloned gene, and is proving a powerful tool for investigating gene function. For reviews, see e.g. Fire (1999) *RNA-triggered gene silencing*. Trends in Genetics 15:358-363; or Kuwabara & Coulson (2000) *RNAi-prospects for a general technique for determining gene function*. Parasitology Today 16:347-349. When double-stranded RNA (dsRNA) corresponding to a sense and antisense sequence of an endogenous mRNA is introduced into a cell, the cognate mRNA is degraded and the gene is silenced. This type of posttranscriptional gene silencing (PTGS) was first discovered in *C. elegans* (Fire et al., (1998) Nature 391:806-811). RNA interference has recently been used for targeting nearly 90% of predicted genes on *C. elegans* chromosome I (Fraser et al. (2000) Nature 408: 325-330) and 96% of predicted genes on *C. elegans* chromosome III (Gönczy et al. (2000) Nature 408:331-336).

TABLE I

Alignment of polypeptides in Protein Cluster II: "*" = identical or conserved residues in all sequences in the alignment.

```

SEQ_ID_NO_4 -----
SEQ_ID_NO_6 -----
SEQ_ID_NO_2 MTENSLSEMASKSWLNFLTFLYGSAIGFILFSQLLSILLGEGDTQTNVLHNDPHARHSD 60

SEQ_ID_NO_4 -----NTGVTDKLYQKMILCWIMTGPQNLEKKIRRIDTWA 37
SEQ_ID_NO_6 DNGQNHLEGQMNFNADSSQHKDENTDIAENLYQKVRILCWVMTGPQNLEKKAKHVKATWA 60
SEQ_ID_NO_2 DNGQNHLEGGQMNFNADSSQRKDENTEIAENLYXQVKILCWVMTGSQNLQKKAKHVKATWA 120
                **      **      ***** ** ** ** **      ***

SEQ_ID_NO_4 QGCNKALFMSSKENKDFSTVGLHTKEDRNQLSWKIVKAFLYAHDHYLEYMDWFMKADDDI 97
SEQ_ID_NO_6 QRCNKVLFMSSEENKDFPAVGLKTKEGRDQLYWKTIKAFQYVHEHYLEDADWFLKADDDT 120
SEQ_ID_NO_2 QRCLKVFFMSSEENKDFRAVGLKTKAGRDELYWKTINLF----- 159
      * * *   *****   *** ** * * * *


SEQ_ID_NO_4 CIYITLDNLKWLNTNYPDESTYFGKRFKHCRKQDYMTGGAGYVLSKE----- 145
SEQ_ID_NO_6 --YVILDNLRWLLSKYDPEEPIYFGRRFKPYVKQGYMSGGAGYVLSKEALKRFVDAFKTD 178
SEQ_ID_NO_2 -----

SEQ_ID_NO_4 -----
SEQ_ID_NO_6 KCTHSSSIEDLALGRCMEIMNVEAGDSRDTIGKETFHFPVPEHHLIKGYLPRTFWYWNYN 238
SEQ_ID_NO_2 -----

SEQ_ID_NO_4 -----
SEQ_ID_NO_6 YPPVEGPGCCSDLAVSFHYVDSTTMYELEYLVYHLRPYGYLYRYQPTLPERILKEISQA 298
SEQ_ID_NO_2 -----

SEQ_ID_NO_4 -----
SEQ_ID_NO_6 NKNETKVKLGNP 311
SEQ_ID_NO_2 -----

```



CLAIMS

1. An isolated nucleic acid molecule selected from:
 - (a) nucleic acid molecules comprising a nucleotide sequence as shown in SEQ ID NO: 1 or 3;
 - (b) nucleic acid molecules comprising a nucleotide sequence capable of hybridizing, under stringent hybridization conditions, to a nucleotide sequence complementary to the polypeptide coding region of a nucleic acid molecule as defined in (a); and
 - (c) nucleic acid molecules comprising a nucleic acid sequence which is degenerate as a result of the genetic code to a nucleotide sequence as defined in (a) or (b).
2. An isolated polypeptide encoded by the nucleic acid molecule according to claim 1.
3. The isolated polypeptide according to claim 2 having an amino acid sequence shown as SEQ ID NO: 2 or 4 in the Sequence Listing
4. A vector harboring the nucleic acid molecule according to claim 1.
5. A replicable expression vector which carries and is capable of mediating the expression of a nucleotide sequence according to claim 1.
6. A cultured host cell harboring a vector according to claim 4 or 5.
7. A process for production of a polypeptide, comprising culturing a host cell according to claim 6 under conditions whereby said polypeptide is produced, and recovering said polypeptide.
8. A method for identifying an agent capable of modulating a nucleic acid molecule according to claim 1, comprising
 - (i) providing a cell comprising the said nucleic acid molecule;

- (ii) contacting said cell with a candidate agent; and
- (iii) monitoring said cell for an effect that is not present in the absence of said candidate agent.

9
2
3
4
5
6
7
8
9
0

SEQUENCE LISTING

<110> Pharmacia AB

<120> Protein Cluster II

<130> 00404

<160> 6

<170> PatentIn version 3.0

<210> 1

<211> 505

<212> DNA

<213> human

<220>

<221> CDS

<222> (21)..(497)

<220>

<221> misc_feature

<222> (297)..()

<223> n=a, g, c or t

<400> 1

gcaagaggga gccacggccg atg aca gaa aat tca ctt tcc gag atg gcc tct	53
Met Thr Glu Asn Ser Leu Ser Glu Met Ala Ser	
1 5 10	

aaa tcc tgg ctg aat ttt tta acc ttc ctc tat gga tgc gca ata ggg	101
Lys Ser Trp Leu Asn Phe Leu Thr Phe Leu Tyr Gly Ser Ala Ile Gly	
15 20 25	

ttt att tta ttt tct cag cta ctt agt att ttg ttg gga gaa gag ggt	149
Phe Ile Leu Phe Ser Gln Leu Leu Ser Ile Leu Leu Gly Glu Glu Gly	
30 35 40	

gac acc cag act aat gtt ctt cat aat gat cct cat gcg agg cat tca	197
Asp Thr Gln Thr Asn Val Leu His Asn Asp Pro His Ala Arg His Ser	
45 50 55	

gat gat aat gga cag aat cat cta gga gga caa atg aac ttc aat gca	245
Asp Asp Asn Gly Gln Asn His Leu Gly Gly Gln Met Asn Phe Asn Ala	
60 65 70 75	

gat tct agc caa cgt aaa gat gag aac aca gaa atc gct gaa aac ctc	293
Asp Ser Ser Gln Arg Lys Asp Glu Asn Thr Glu Ile Ala Glu Asn Leu	
80 85 90	

tat nag caa gtt aaa att ctt tgc tgg gtt atg aca ggc tct caa aac	341
Tyr Xaa Gln Val Lys Ile Leu Cys Trp Val Met Thr Gly Ser Gln Asn	
95 100 105	

cta cag aaa aag gcc aaa cat gtc aaa gct aca tgg gcc cag cgt tgt	389
Leu Gln Lys Lys Ala Lys His Val Lys Ala Thr Trp Ala Gln Arg Cys	
110 115 120	

cta aaa gta ttt ttt atg agt tca gaa gaa aat aaa gac ttc cgt gct 437
 Leu Lys Val Phe Phe Met Ser Ser Glu Glu Asn Lys Asp Phe Arg Ala
 125 130 135

gtg gga ttg aaa acc aaa gca ggc aga gat gag cta tac tgg aaa aca 485
 Val Gly Leu Lys Thr Lys Ala Gly Arg Asp Glu Leu Tyr Trp Lys Thr
 140 145 150 155

att aac ctt ttc agtatggt 505
 Ile Asn Leu Phe

<210> 2
 <211> 159
 <212> PRT
 <213> human

<400> 2
 Met Thr Glu Asn Ser Leu Ser Glu Met Ala Ser Lys Ser Trp Leu Asn
 1 5 10 15

Phe Leu Thr Phe Leu Tyr Gly Ser Ala Ile Gly Phe Ile Leu Phe Ser
 20 25 30

Gln Leu Leu Ser Ile Leu Leu Gly Glu Glu Gly Asp Thr Gln Thr Asn
 35 40 45

Val Leu His Asn Asp Pro His Ala Arg His Ser Asp Asp Asn Gly Gln
 50 55 60

Asn His Leu Gly Gly Gln Met Asn Phe Asn Ala Asp Ser Ser Gln Arg
 65 70 75 80

Lys Asp Glu Asn Thr Glu Ile Ala Glu Asn Leu Tyr Xaa Gln Val Lys
 85 90 95

Ile Leu Cys Trp Val Met Thr Gly Ser Gln Asn Leu Gln Lys Lys Ala
 100 105 110

Lys His Val Lys Ala Thr Trp Ala Gln Arg Cys Leu Lys Val Phe Phe
 115 120 125

Met Ser Ser Glu Glu Asn Lys Asp Phe Arg Ala Val Gly Leu Lys Thr
 130 135 140

Lys Ala Gly Arg Asp Glu Leu Tyr Trp Lys Thr Ile Asn Leu Phe
 145 150 155

<210> 3
 <211> 489
 <212> DNA
 <213> human

<220>
 <221> CDS
 <222> (55)..(489)

<400> 3
catctaaaaa gactgatgaa gttgattgca aatgctagtc atcataaata ccag aac 57
Asn
1

aca ggt gtc act gac aaa ctc tat caa aag atg aaa att ctt tgc tgg 105
Thr Gly Val Thr Asp Lys Leu Tyr Gln Lys Met Lys Ile Leu Cys Trp
5 10 15

att atg aca gga cct caa aat cta gaa aaa aag atc aga cgc atc aga 153
Ile Met Thr Gly Pro Gln Asn Leu Glu Lys Lys Ile Arg Arg Ile Arg
20 25 30

gat aca tgg gcc cag ggt tgc aat aaa gcg ttg ttt atg agc tca aaa 201
Asp Thr Trp Ala Gln Gly Cys Asn Lys Ala Leu Phe Met Ser Ser Lys
35 40 45

gaa aat aaa gac ttc tct act gtg gga tta cac acc aaa gaa gac aga 249
Glu Asn Lys Asp Phe Ser Thr Val Gly Leu His Thr Lys Glu Asp Arg
50 55 60 65

aac caa ctg tcc tgg aaa ata gtt aaa gct ttt cta tat gct cat gac 297
Asn Gln Leu Ser Trp Lys Ile Val Lys Ala Phe Leu Tyr Ala His Asp
70 75 80

cat tat ctg gaa tac atg gat tgg ttc atg aaa gca gat gat gat ata 345
His Tyr Leu Glu Tyr Met Asp Trp Phe Met Lys Ala Asp Asp Asp Ile
85 90 95

tgt ata tat atc aca ttg gac aac ttg aaa tgg ctt ctc aca aac tat 393
Cys Ile Tyr Ile Thr Leu Asp Asn Leu Lys Trp Leu Leu Thr Asn Tyr
100 105 110

aac cct gat gaa tcc act tac ttt ggg aaa aga ttt aag cac tgc aga 441
Asn Pro Asp Glu Ser Thr Tyr Phe Gly Lys Arg Phe Lys His Cys Arg
115 120 125

aaa cag gac tac atg act gga gga gca gga tat gta ctg agc aaa gaa 489
Lys Gln Asp Tyr Met Thr Gly Gly Ala Gly Tyr Val Leu Ser Lys Glu
130 135 140 145

<210> 4
<211> 145
<212> PRT
<213> human

<400> 4
Asn Thr Gly Val Thr Asp Lys Leu Tyr Gln Lys Met Lys Ile Leu Cys
1 5 10 15

Trp Ile Met Thr Gly Pro Gln Asn Leu Glu Lys Lys Ile Arg Arg Ile
20 25 30

Arg Asp Thr Trp Ala Gln Gly Cys Asn Lys Ala Leu Phe Met Ser Ser
35 40 45

Lys Glu Asn Lys Asp Phe Ser Thr Val Gly Leu His Thr Lys Glu Asp
50 55 60

Arg Asn Gln Leu Ser Trp Lys Ile Val Lys Ala Phe Leu Tyr Ala His
 65 70 75 80
 Asp His Tyr Leu Glu Tyr Met Asp Trp Phe Met Lys Ala Asp Asp Asp
 85 90 95
 Ile Cys Ile Tyr Ile Thr Leu Asp Asn Leu Lys Trp Leu Leu Thr Asn
 100 105 110
 Tyr Asn Pro Asp Glu Ser Thr Tyr Phe Gly Lys Arg Phe Lys His Cys
 115 120 125
 Arg Lys Gln Asp Tyr Met Thr Gly Gly Ala Gly Tyr Val Leu Ser Lys
 130 135 140
 Glu
 145

<210> 5
 <211> 1560
 <212> DNA
 <213> human

<220>
 <221> CDS
 <222> (2)..(934)

<400> 5
 a gat aat gga cag aat cat cta gaa gga caa atg aac ttc aat gca gat 49
 Asp Asn Gly Gln Asn His Leu Glu Gly Gln Met Asn Phe Asn Ala Asp
 1 5 10 15
 tct agc caa cat aaa gat gag aac aca gac att gct gaa aac ctc tat 97
 Ser Ser Gln His Lys Asp Glu Asn Thr Asp Ile Ala Glu Asn Leu Tyr
 20 25 30
 cag aaa gtt aga att ctt tgc tgg gtt atg acc ggc cct caa aac cta 145
 Gln Lys Val Arg Ile Leu Cys Trp Val Met Thr Gly Pro Gln Asn Leu
 35 40 45
 gag aaa aag gcc aaa cac gtc aaa gct act tgg gcc cag cgt tgt aac 193
 Glu Lys Lys Ala Lys His Val Lys Ala Thr Trp Ala Gln Arg Cys Asn
 50 55 60
 aaa gtg ttg ttt atg agt tca gaa gaa aat aaa gac ttc cct gct gtg 241
 Lys Val Leu Phe Met Ser Ser Glu Glu Asn Lys Asp Phe Pro Ala Val
 65 70 75 80
 gga ctg aaa acc aaa gaa ggc aga gat caa cta tac tgg aaa aca att 289
 Gly Leu Lys Thr Lys Glu Gly Arg Asp Gln Leu Tyr Trp Lys Thr Ile
 85 90 95
 aaa gct ttt cag tat gtt cat gaa cat tat tta caa gat gct gat tgg 337
 Lys Ala Phe Gln Tyr Val His Glu His Tyr Leu Gln Asp Ala Asp Trp
 100 105 110
 ttt ttg aaa gca gat gat gac acg tat gtc ata cta gac aat ttg agg 385
 Phe Leu Lys Ala Asp Asp Asp Thr Tyr Val Ile Leu Asp Asn Leu Arg
 115 120 125

tgg ctt ctt tca aaa tac gac cct gaa gaa ccc att tac ttt ggg aga	433
Trp Leu Leu Ser Lys Tyr Asp Pro Glu Glu Pro Ile Tyr Phe Gly Arg	
130 135 140	
aga ttt aag cct tat gta aag cag ggc tac atg agt gga gga gca gga	481
Arg Phe Lys Pro Tyr Val Lys Gln Gly Tyr Met Ser Gly Gly Ala Gly	
145 150 155 160	
tat gta cta agc aaa gaa gcc ttg aaa aga ttt gtt gat gca ttt aaa	529
Tyr Val Leu Ser Lys Glu Ala Leu Lys Arg Phe Val Asp Ala Phe Lys	
165 170 175	
aca gac aag tgt aca cat agt tcc tcc att gaa gac tta gca ctg ggg	577
Thr Asp Lys Cys Thr His Ser Ser Ser Ile Glu Asp Leu Ala Leu Gly	
180 185 190	
aga tgc atg gaa att atg aat gta gaa gca gga gat tcc aga gat acc	625
Arg Cys Met Glu Ile Met Asn Val Glu Ala Gly Asp Ser Arg Asp Thr	
195 200 205	
att gga aaa gaa act ttt cat ccc ttt gtg cca gaa cac cat tta att	673
Ile Gly Lys Glu Thr Phe His Pro Phe Val Pro Glu His His Leu Ile	
210 215 220	
aaa ggt tat cta cct aga acg ttt tgg tac tgg aat tac aac tat tat	721
Lys Gly Tyr Leu Pro Arg Thr Phe Trp Tyr Trp Asn Tyr Asn Tyr Tyr	
225 230 235 240	
cct cct gta gag ggt cct ggt tgc tgc tct gat ctt gca gtt tct ttt	769
Pro Pro Val Glu Gly Pro Gly Cys Cys Ser Asp Leu Ala Val Ser Phe	
245 250 255	
cac tat gtt gat tct aca acc atg tat gag tta gaa tac ctc gtt tat	817
His Tyr Val Asp Ser Thr Thr Met Tyr Glu Leu Glu Tyr Leu Val Tyr	
260 265 270	
cat ctt cgt cca tat ggt tat tta tac aga tat caa cct acc tta cct	865
His Leu Arg Pro Tyr Gly Tyr Leu Tyr Arg Tyr Gln Pro Thr Leu Pro	
275 280 285	
gaa cgt ata cta aag gaa att agt caa gca aac aaa aat gaa gat aca	913
Glu Arg Ile Leu Lys Glu Ile Ser Gln Ala Asn Lys Asn Glu Asp Thr	
290 295 300	
aaa gtg aag tta gga aat cct tgaaagaaaa tcatgaatga acaaaggtaa	964
Lys Val Lys Leu Gly Asn Pro	
305 310	
tatgtctagc actgcactga aaaaggactt ctgcatttct gacatagaac actggaatcc	1024
cagtgaggaa ttctaagtga acattcctta tagaaacctt tcacatgaat gactataaac	1084
tgaagcttta aatgagctgt gaagtgtgtt aaaatgtgtt ttgatacagt aatatataaa	1144
tatgtctata tatatgagga acttgtgttt tttaaattggt ggccaggtag aggaactaga	1204
aaagagattt tgttgccctgt tttctgacca tctgtgttat tgctactgag aaactaaaat	1264
agtaaattta ctaaaactac actgcacccat gttagtaata aacagatctg ccttaaagaa	1324

aagaaaattt tagaaagaaa tattgttgct cagtgttggt aatatagctc aagaattgag 1384
 tttatatattg cagtatgcta taaatgatac cccctacca caccacaca cacagttttt 1444
 gtctaatagaa aatgttgctg tgattattta taattggttag tattttctcc agaagaagct 1504
 aaaataagac tggcacttac cctgaagtgc attaataaaa ccacacttta aaatta 1560

<210> 6
 <211> 311
 <212> PRT
 <213> human

<400> 6
 Asp Asn Gly Gln Asn His Leu Glu Gly Gln Met Asn Phe Asn Ala Asp
 1 5 10 15
 Ser Ser Gln His Lys Asp Glu Asn Thr Asp Ile Ala Glu Asn Leu Tyr
 20 25 30
 Gln Lys Val Arg Ile Leu Cys Trp Val Met Thr Gly Pro Gln Asn Leu
 35 40 45
 Glu Lys Lys Ala Lys His Val Lys Ala Thr Trp Ala Gln Arg Cys Asn
 50 55 60
 Lys Val Leu Phe Met Ser Ser Glu Glu Asn Lys Asp Phe Pro Ala Val
 65 70 75 80
 Gly Leu Lys Thr Lys Glu Gly Arg Asp Gln Leu Tyr Trp Lys Thr Ile
 85 90 95
 Lys Ala Phe Gln Tyr Val His Glu His Tyr Leu Gln Asp Ala Asp Trp
 100 105 110
 Phe Leu Lys Ala Asp Asp Asp Thr Tyr Val Ile Leu Asp Asn Leu Arg
 115 120 125
 Trp Leu Leu Ser Lys Tyr Asp Pro Glu Glu Pro Ile Tyr Phe Gly Arg
 130 135 140
 Arg Phe Lys Pro Tyr Val Lys Gln Gly Tyr Met Ser Gly Gly Ala Gly
 145 150 155 160
 Tyr Val Leu Ser Lys Glu Ala Leu Lys Arg Phe Val Asp Ala Phe Lys
 165 170 175
 Thr Asp Lys Cys Thr His Ser Ser Ser Ile Glu Asp Leu Ala Leu Gly
 180 185 190
 Arg Cys Met Glu Ile Met Asn Val Glu Ala Gly Asp Ser Arg Asp Thr
 195 200 205
 Ile Gly Lys Glu Thr Phe His Pro Phe Val Pro Glu His His Leu Ile
 210 215 220

Lys Gly Tyr Leu Pro Arg Thr Phe Trp Tyr Trp Asn Tyr Asn Tyr Tyr
225 230 235 240

Pro Pro Val Glu Gly Pro Gly Cys Cys Ser Asp Leu Ala Val Ser Phe
245 250 255

His Tyr Val Asp Ser Thr Thr Met Tyr Glu Leu Glu Tyr Leu Val Tyr
260 265 270

His Leu Arg Pro Tyr Gly Tyr Leu Tyr Arg Tyr Gln Pro Thr Leu Pro
275 280 285

Glu Arg Ile Leu Lys Glu Ile Ser Gln Ala Asn Lys Asn Glu Asp Thr
290 295 300

Lys Val Lys Leu Gly Asn Pro
305 310

00404-SE

ABSTRACT

The present invention relates to the identification of a human gene family expressed in metabolically relevant tissues. The genes encode a group polypeptides referred to as "Protein Cluster II" which are predicted to be useful in the diagnosis of metabolic diseases, such as obesity and diabetes, as well as in the identification of agents useful in the treatment of the said diseases.

00404-SE